As the population of People Living with Human Immunodeficiency Virus (PLWH) ages in the era of effective antiretroviral therapy, the risk of non-HIV associated cancers is increasing, and now accounts for most cancer diagnosed in PLWH. Moreover, PLWH experience worse outcomes compared with individuals with similar cancer who do not have HIV infection. In addition, most clinical trials testing novel therapeutic agents excluded PLWH, including immunotherapeutic approaches that have revolutionized cancer therapy.
Leadership
Chair
Vice Chair
International Vice Chair
The overall goals of the Solid Tumor Working Group include to:
- Evaluate the efficacy and safety of novel therapeutic approaches, which includes immunotherapeutic approaches, for the treatment of PLWH
- Evaluate diagnostic and therapeutic approaches unique to PLWH in resource limited international settings
- Evaluate the spectrum of cancer diagnoses and symptom burden among PLWH at U.S. and international sites
- Develop new initiatives for cancer prevention/control in PLWH.
Several trials addressing these goals are currently in progress and/or are in development by the Solid Tumor Working Group. Please check out our Current Studies.